Gastrointestinal absorption of pravastatin in healthy subjects.
The bioavailability of pravastatin, a hypocholesterolmic agent, may be enhanced by decreasing its exposure to stomach contents, where it may be converted nonenzymatically to a relatively inactive metabolite. The pharmacokinetics of pravastatin and its metabolite were determined after infusion of pravastatin directly into the stomach (locus for greatest bioavailability for the metabolite), duodenum (greatest bioavailability for pravastatin), jejunum, or ileum. An enterically coated formulation of pravastatin may increase its bioavailability.
Triscari
J
J
Bristol-Myers Squibb, Princeton, New Jersey, USA.
O'Donnell
D
D
Zinny
M
M
Pan
H Y
HY
D000328:Adult; D001682:Biological Availability; D004334:Drug Administration Schedule; D004386:Duodenum / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D007082:Ileum / Q000378:metabolism; D007408:Intestinal Absorption; D007441:Intubation, Gastrointestinal; D007583:Jejunum / Q000378:metabolism; D008297:Male; D017035:Pravastatin / Q000008:administration & dosage / Q000493:pharmacokinetics*
D017035:Pravastatin